Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Changing Therapeutic Landscape and the Role of the Pharmacist
ACPE Number:0204-0000-25-414-H01-P Content Release Date: February 26, 2026 Expiration Date: February 26, 2027 Activity Type: Application-based CE Credits: 1.5 contact hours (0.15 CEUs) Activity Fee: Free
Activity Overview
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated, rare disorder leading to muscle weakness and sensory disturbance. It can be debilitating and lead to impaired mobility, difficulty or inability to perform activities of daily living, and severe disability. Conventional therapies are beneficial for patients with CIDP, but there are limitations associated with these therapies requiring consideration of the individual needs of the patient. New and emerging therapies including FcRn antagonists provide targeted therapies, and pharmacists must be aware of the current clinical evidence, appropriate patient selection, identifying where these agents fit within the current treatment algorithm, and methods to transition patients to these therapies to provide individualized, patient-centered care and improve patient outcomes.
This educational activity will discuss the pathophysiology of CIDP as well as the incidence, prevalence, clinical course, and burden of disease. A review of the current guideline-recommended therapies will be discussed, including any treatment limitations. The most recent clinical evidence of new and emerging therapies in CIDP will be explored and opportunities for pharmacists to improve patient care through optimizing therapy, medication monitoring, providing access to medications, patient education, promoting adherence, care coordination, and adjunct care including recommending appropriate vaccinations.
*Please note, this activity was presented live on December 8, 2025 as part of the ASHP 2025 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This 1.5 hour educational activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, and ambulatory clinics who care for or are interested in the care of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
At the conclusion of this activity, participants should be able to:
Describe the pathophysiology, prevalence/incidence, burden of illness, and identification of patients with CIDP.
Evaluate treatment guidelines and conventional therapies for CIDP.
Analyze evidence of new and emerging treatments for CIDP including their mechanism of action, pharmacology, current clinical trial data including safety and efficacy, and where these agents may fit into practice.
Apply evidence-based approaches to individualize patient-centered treatment and counseling to improve patient safety, adherence, access, and outcomes.
Claire Spahn is a clinical pharmacist at Stanford Health Care in Stanford, California. Dr. Spahn received her BS(Pharm degree from Trinity College, Dublin, Ireland, her PharmD degree from Western University of Health Sciences in Los Angeles and an MS degree from University of Florida. She completed a PGY1 acute care pharmacy residency at Stanford Health Care, Stanford California. Dr. Spahn practices in specialty ambulatory care clinics including neurology and pharmacogenomics.
Neelam Goyal, MD Clinical Professor, Department of Neurology and Neurological Sciences, Division of Neuromuscular Medicine Stanford University Palo Alto, California
Neelam Goyal is a Clinical Professor of Neurology and Neurological Sciences in the division of Neuromuscular Medicine. She earned her medical degree at SUNY Downstate in Brooklyn, NY. Subsequently, she completed her neurology residency, which included a chief year, followed by a fellowship year in neurophysiology, specializing in neuromuscular disorders and EMG nerve conduction studies at Stanford University Medical Hospital. Dr. Goyal focuses on the diagnosis, management, and electrophysiological testing of neuromuscular disorders, including SFEMG. Her expertise extends to immune-mediated disorders such as myositis, myasthenia gravis, CIDP, and vasculitis. Her research interests involve monitoring and managing the short and long-term toxicity of immunosuppressive agents. She is actively involved in a grant-supported project investigating steroid toxicity in patients with myasthenia gravis.
Jeffery S. Vender, MD, MCCM, MBA is the Emeritus, Harris Family Foundation Chairman of the Department of Anesthesiology at NorthShore University Health System in Evanston, Illinois and a Clinical Professor at the University of Chicago Pritzker School Of Medicine in Chicago, Illinois. He is a past member of the NorthShore University Health System Faculty Practice Associates Board of Directors, Past Chair of the Medical Executive Committee for the Professional Staff at NorthShore and previously served on Northshore’s Board of Directors. Dr. Vender served as Chair of Anesthesia from 1990-2015 and received an appointment of adjunct Professor of Biomedical Engineering at Northwestern University. He served as the Director of the Critical Care Services at Evanston Hospital from 1987-2000 and the Interim Chairman at Northwestern University Department of Anesthesiology from July 1999 until October 2000. Dr. Vender has participated and Chaired numerous state and national committees of various medical organizations, edited several medical texts, has published over 135 articles and book chapters and has been an invited lecturer at over 250 national and international meetings on topics of anesthesiology, critical care, organizational change, and leadership. In addition, Dr. Vender serves as an editor and/or reviewer for many medical journals.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Neelam Goyal: Principal Investigator and Advisor – argenx
All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP.
Supported by an independent educational grant from argenx.
